Novel therapies for cutaneous T-cell lymphoma: what does the future hold? - Wikidata - wikimedia - TriplyDB

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

http://www.wikidata.org/entity/Q38176398

about

Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.Monoclonal antibodies against cutaneous T-cell lymphomas.BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.

P2860

Q26746551-1190F94B-770D-4D55-B101-DB60F776F6D1 Q35890561-83ADFD6C-F952-47DB-A622-F62BA30231CE Q47836540-81D2B6E2-D6FB-400A-8D46-2379FE3430DA Q48098653-1F1C1F43-2E37-43BF-A554-701F994134EE Q48167908-47198318-1034-4EAE-A11A-8D9F08D33BD7 Q48309242-23E5AA8B-8FF3-43C3-BA91-ED03CD8BAB68 Q51803389-552E0803-D193-42AB-BE73-650C7FABBBA4 Q52976582-9CE1EF89-BF28-4CBF-BD1E-B330825FFA59

P2860

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

http://www.wikidata.org/entity/Q38176398

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

@en

type

label

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

@en

prefLabel

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

@en

P1433

Q38176398-5B8EF245-B2E5-4BA6-896D-704AE5B7CE36

P1476

Q38176398-E6D497CD-9465-4C39-B4B3-FF9BAF2AEEC3

P2093

Q38176398-0722E9B4-12F0-4524-9D3D-959480A8A18E

Q38176398-98D9B814-7FE7-42A5-9941-E2AD07CB83A0

Q38176398-B533023E-87BB-4934-8815-18235E14415D

Q38176398-CE59A92A-39F6-4993-B7D7-732920A1ACB9

Q38176398-D846248A-CF81-466D-93D8-EDB04C96689E

Q38176398-FE6DDB6D-D709-4FD7-9358-0E42B839F00B

P2860

Q38176398-001700A7-B882-45D8-87E1-D0FB370BAE9C

Q38176398-018A5429-6648-4D6D-8D29-30EFE3457B92

Q38176398-07A8C7D3-E93B-432B-8369-596B13883946

Q38176398-0E099430-DF95-4C2D-B243-FF303C107BB6

Q38176398-1777A65D-C610-413A-BD07-4A001A5497B3

Q38176398-179E71D9-19FD-46E4-A2C0-1739B9DBB635

Q38176398-1940241A-7C9B-40CC-87D0-4B05F4D33F7F

Q38176398-19C90350-962A-47F8-9A5C-A25FF8DA9BB2

Q38176398-1B43812E-B879-46BA-AEDA-1F00FB1171B9

Q38176398-1B649122-2538-486E-9846-94A49EDE3DBC

P304

Q38176398-0880A4C3-F743-441D-95AD-71098A37CFD9

P31

Q38176398-E8DB6CB4-ED21-4117-A73B-FA506BD9A618

P356

Q38176398-CF152B62-7CDB-4069-A93A-DA51C5A6199F

P407

Q38176398-2C9CA4C2-84B7-4F60-9AC9-E40994EE92A8

P433

Q38176398-00C9E0D1-54EA-442E-AD9E-5E2262D6A63E

P478

Q38176398-BD7064B6-6BA6-4C5C-A2D9-B1DD9A38EE13

P50

Q38176398-5584DBA3-8642-45D5-9DB3-CE290A9BBD19

P577

Q38176398-4A48A453-1C93-4239-A18C-4A421950C097

P698

Q38176398-9B61E0C5-F0C1-466E-BDFE-89B9923BC5D8

P356

13543784.2014.876407

P1433

Expert Opinion on Investigational Drugs

P1476

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

@en

P2093

Antonio Cozzio

http://www.w3.org/2001/XMLSchema#string

Emmanuella Guenova

http://www.w3.org/2001/XMLSchema#string

Mitchell P Levesque

http://www.w3.org/2001/XMLSchema#string

Reinhard Dummer

http://www.w3.org/2001/XMLSchema#string

Sima Rozati

http://www.w3.org/2001/XMLSchema#string

Wolfram Hoetzenecker

http://www.w3.org/2001/XMLSchema#string

P2860

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Brentuximab vedotin

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Nivolumab plus ipilimumab in advanced melanoma.

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

P304

457-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.876407

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuella Guenova

P577

2014-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24397291

http://www.w3.org/2001/XMLSchema#string